Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.

Asian Pacific journal of cancer prevention : APJCP - 1 Nov 2020

Mohan Anant, Ansari Ashraf, Masroor Mirza, Saxena Alpana, Pandey R M, Upadhyay Ashish, Luthra Kalpana, Khilnani G C, Jain Deepali, Kumar Rakesh, Guleria Randeep

Abstract excerpt

BACKGROUND: EGFR over-expression plays a key role in the development and progression of lung cancer. However, its status as a prognostic biomarker for survival outcomes is unclear. OBJECTIVES: To evaluate the prognostic utility of serum EGFR mRNA expression in Non-Small cell lung cancer (NSCLC) for treatment response and survival. METHODS: EGFR mRNA levels were determined in serum using quantitative reverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemoradiotherapy

Share to ErbB Receptors

Share to Follow-Up Studies

Share to ROC Curve

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33247670
DOI: 10.31557/APJCP.2020.21.11.3153
PMCID: PMC8033130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.PMID 33247670Read ↗

Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancerSemantic proximity Read ↗

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.Semantic proximity Read ↗

Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer? A meta-analysis.Semantic proximity Read ↗

Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application.Semantic proximity Read ↗

Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.Semantic proximity Read ↗

Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.Semantic proximity Read ↗

Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.Semantic proximity Read ↗

Highly sensitive detection of EGFR L858R mutation at the mRNA level.Semantic proximity Read ↗

Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma.Semantic proximity Read ↗

The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancerSemantic proximity Read ↗

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.